Palifosfamide
- Generic Name
- Palifosfamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11Cl2N2O2P
- CAS Number
- 31645-39-3
- Unique Ingredient Identifier
- 6A4U6NN813
- Background
Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), lymphoma (unspecified), and sarcoma.
- Associated Conditions
- -
- Associated Therapies
- -
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
- Conditions
- Adult TeratomaMalignant Extragonadal Non-Seminomatous Germ Cell TumorRecurrent Malignant Testicular Germ Cell TumorMalignant Extragonadal Germ Cell TumorStage IV Extragonadal SeminomaStage IV Ovarian Germ Cell TumorAdult Central Nervous System Germ Cell TumorRecurrent Ovarian Germ Cell TumorExtragonadal SeminomaStage IV Extragonadal Non-Seminomatous Germ Cell Tumor
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT01808534
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01703754
- Locations
- 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Billings Clinic, Billings, Montana, United States
🇺🇸Signal Point Clinical Research Center, Middletown, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.